Repligen (RGEN) Tops Q4 EPS by 10c, Guidance Falls Short of Conensus
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $169.04 +1.32%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.68, $0.10 better than the analyst estimate of $0.58. Revenue for the quarter came in at $186.8 million versus the consensus estimate of $186.3 million.
GUIDANCE:
Repligen sees FY2023 EPS of $2.61-$2.69, versus the consensus of $2.92. Repligen sees FY2023 revenue of $760-800 million, versus the consensus of $800 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- XP Inc. (XP) Tops Q2 EPS by 8c
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
